Authorized purpose: MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.
Clinical role
Breast-density assessment support
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Adjunctive information only; not diagnostic, and patient-management decisions should not be made solely from MammoScreen BD.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: DICOM 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or DBT systems using 2D synthetic mammography; the FDA labeling describes Hologic and GE compatible systems.
Who uses it?Intended users: Physicians interpreting mammograms, including radiologists
What does the software produce?Output: A breast-density category of A, B, C, or D; output is provided as JSON and can be displayed as a DICOM Structured Report, DICOM Secondary Capture Image, or in patient worklists through compatible third-party software.
What is its most important limitation?Key limitation: Adjunctive information only; not diagnostic, and patient-management decisions should not be made solely from MammoScreen BD.
Clinical takeaway. Clinical role: MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.
Evidence takeaway. Evidence from the reviewed source record: Standalone clinical validation compared MammoScreen BD density categories with consensus from five breast radiologists; the FDA packet describes validation across compatible FFDM and DBT inputs.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.
DICOM 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or DBT systems using 2D synthetic mammography; the FDA labeling describes Hologic and GE compatible systems.
A breast-density category of A, B, C, or D; output is provided as JSON and can be displayed as a DICOM Structured Report, DICOM Secondary Capture Image, or in patient worklists through compatible third-party software.
Standalone clinical validation compared MammoScreen BD density categories with consensus from five breast radiologists; the FDA packet describes validation across compatible FFDM and DBT inputs.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Standalone clinical validation compared MammoScreen BD density categories with consensus from five breast radiologists; the FDA packet describes validation across compatible FFDM and DBT inputs.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
MammoScreen BD breast-density clinical validation
DesignStandalone clinical validation against consensus reference
PopulationAsymptomatic women aged 40 years or older undergoing screening mammography on compatible FFDM and DBT systems
Scopeexact submission
Tested versionMammoScreen BD submitted in K243685; build not stated
IndependenceIndependence not established
K243685
Reference standard was the consensus of five breast radiologists; exact enrollment count was not used here because it was not consistently exposed in the extracted packet text.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.
Public pricing
MammoScreen family SaaS priced per successfully processed mammogram; the official FAQ also states that version updates are automatic.
Product family
Checked 2026-09-07
The reviewed FAQ does not publish an exact amount, currency, geography, or contract term. Cloud de-identification/deletion statements were not treated as a scoped security audit.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or DBT systems using 2D synthetic mammography; the FDA labeling describes Hologic and GE compatible systems.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA submission describes DICOM input and JSON output, with optional DICOM SR, DICOM Secondary Capture, and worklist display through third-party software; local interface compatibility remains site-specific.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: A breast-density category of A, B, C, or D; output is provided as JSON and can be displayed as a DICOM Structured Report, DICOM Secondary Capture Image, or in patient worklists through compatible third-party software.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A breast-density category of A, B, C, or D; output is provided as JSON and can be displayed as a DICOM Structured Report, DICOM Secondary Capture Image, or in patient worklists through compatible third-party software.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA submission describes DICOM input and JSON output, with optional DICOM SR, DICOM Secondary Capture, and worklist display through third-party software; local interface compatibility remains site-specific.
Therapixel's own page says Therapixel and its operations for MammoScreen are ISO/IEC 27001 certified by an independent certification body. The page gives no certificate number, scope statement, issue date or expiry, and the certificate was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-07Last searched
23Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, vendor faq, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Therapixel MammoScreen reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Therapixel's adoption page describes general US screening mammography policy; it states no coding or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-07 - Exact FDA submission
Current onboarding, competency, and support commitments were not established.
Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission
Local acceptance testing, production monitoring, update control, and drift review were not established.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.